Action NAVB NAVIDEA BIOPHARMACEUTICALS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Navidea Biopharmaceuticals, Inc.

Actions

NAVB

US63937X2027

Temps Différé OTC Markets
Autres places de cotation
 21:40:52 02/05/2024 		Varia. 5j. Varia. 1 janv.
0,035 USD 0,00% Graphique intraday de Navidea Biopharmaceuticals, Inc. -4,89% -36,59%
2023 Navidea Biopharmaceuticals, Inc. annonce ses résultats pour le troisième trimestre et les neuf mois se terminant le 30 septembre 2023 CI
2023 Mise à jour sectorielle : Soins de santé MT

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Navidea Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. Enter Binding Settlement Agreement and Mutual Release
Navidea Biopharmaceuticals, Inc. announced that it expects to receive $0.75 million in funding
Navidea: Q3 Earnings Snapshot
Navidea Biopharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Navidea Biopharmaceuticals, Inc.(OTCPK:NAVB) dropped from S&P TMI Index
Sector Update: Health Care
Top Midday Decliners
Navidea Biopharmaceuticals Says NYSE American Panel Upheld Delisting Decision
Navidea Biopharmaceuticals, Inc. Announces NYSE American’s Decision to Suspend Trading In Its Common Stock
Navidea Biopharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Navidea Biopharmaceuticals, Inc. NAVB Requests Oral Hearing With NYSE Hearing Panel
Navidea Biopharmaceuticals, Inc. Announces Resignation of Malcolm G. Witter as Director, Member of the Audit Committee and Compensation, Nominating and Governance Committee of the Board
Navidea Biopharmaceuticals, Inc. Announces NYSE American Has Commenced Delisting Proceedings and Intent to Appeal NYSE American Determination
Navidea Biopharmaceuticals, Inc. Presses Ahead, Embraces Opportunities
Navidea Biopharmaceuticals, Inc. Announces NYSE American Has Commenced Delisting Proceedings and Intent to Appeal NYSE American Determination
Navidea Biopharmaceuticals, Inc. Announces Executive Changes
Navidea Biopharmaceuticals, Inc. Hires Craig A. Dais, CPA as Chief Financial Officer
Navidea Biopharmaceuticals, Inc. Hires Craig A. Dais, CPA as Chief Financial Officer
Navidea Biopharmaceuticals, Inc. Announces Board Changes
Navidea Biopharmaceuticals, Inc. Welcomes Dana J Moss, JD to Board of Directors; Amit Bhalla Steps Down
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action NAVB
  4. Actualités Navidea Biopharmaceuticals, Inc.
  5. Autres langues